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Abstract
Background and aims: There are a number of gaps in our current quality of care for patients with
inflammatory bowel diseases. This review proposes changes that could be made now to improve
inflammatory bowel disease care.
Methods: Evidence from the literature and clinical experience are presented that illustrate best
practice for improving current quality of care of patients with inflammatory bowel diseases.
Results: Best care for inflammatory bowel disease patients will involve services provided by a
multidisciplinary team, ideally delivered at a centre of excellence and founded on current guidelines.
Dedicated telephone support lines, virtual clinics and networking may also provide models through
which to deliver high-quality, expert integrated patient care. Improved physician–patient collabora-
tion may improve treatment adherence, producing tangible improvements in disease outcomes, and
may also allow patients to better understand the benefits and risks of a disease management plan.
Coaching programmes and tools that improve patient self-management and empowerment are likely to
be supported by payers if these can be shown to reduce long-term disability.protein; HCP, healthcare professional; IMID, immune-mediated inflammatory diseases; MDT,
sentations made during the ‘Leading Change in IBD’meeting held in Madrid on 18–19 January 2013 and
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920 J. Panés et al.Conclusions: Halting disease progression before there is widespread bowel damage and
disability are ideal goals of inflammatory bowel disease management. Improving patient–
physician communication and supporting patients in their understanding of the evidence base
are vital for ensuring patient commitment and involvement in the long-term management of
their condition. Furthermore, there is a need to create more centres of excellence and to
develop inflammatory bowel disease networks to ensure a consistent level of care across
different settings.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V.license.Open access under CC BY-NC-ND Contents
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do better?
Inflammatory bowel diseases (IBDs) are emerging as a
worldwide epidemic, with prevalence of around 1% in
North America and some European countries, and a rapid
increase in incidence reported in Asia, China and Austral-
asia.1 A number of recent reports and publications point to
the burden that this rising tide of IBD is imposing on patients,
healthcare services and society. For example, a comprehen-
sive and large-scale study in Denmark comparing ulcerative
colitis (UC) and Crohn's disease (CD) patients with matched
controls has shown that a diagnosis of IBD increases both
immediate- and long-term risk of mortality.2 Furthermore,
patients with IBD are more likely to be in receipt of disability
allowances than age-matched individuals from the general
population,3 reflecting the impact of an IBD diagnosis on
health-related quality of life and productivity.1.1. Earlier diagnosis, earlier intervention and better
adherence to guidelines
The IMPACT patient survey, conducted in 27 European
countries and sampling responses from almost 5000 IBD
patients (63% CD, 33% UC), highlights a number of gaps in
current clinical care.4 Overall, 18% of IBD patients reported
that they waited over for 5 years before receiving a
diagnosis, and 67% needed emergency care before receiving
a diagnosis. Moreover, 53% reported they felt unable to tell
their doctor something important at a consultation. Other
evidence that suggests that there is room for improvement
in the current care of patients with IBD comes from a recentsurvey of IBD patients in France.5 This questionnaire-based
study found that, contrary to current guideline recommen-
dations, only around 30% of patients with long-standing
extensive colitis received a screening colonoscopy. Further-
more, a US physician survey reported that 29% of physicians
were unaware of guidelines recommending venous throm-
boembolism prophylaxis in hospitalised IBD patients and that
only 35% would provide pharmacological prophylaxis to
hospitalised patients with severe UC.6 There is also evidence
from population-based studies that many patients are still
treated late in the course of their disease, even with
current-day treatment algorithms founded on earlier use of
immunosuppressants and biological therapy.7 One of the
issues that complicate quality of care is the plethora of
guidelines available from a number of professional societies,
covering a range of specific scenarios. At least some of these
may be rapidly outdated and may be difficult to locate or
follow, particularly by non-IBD specialists.
1.2. Preventing long-term disease progression
There is a need for wider appreciation of the progressive
nature of IBD and the importance of early diagnosis and
intervention at earlier stages of disease, ideally before
disease progression occurs.8,9 In CD, there is progressive
digestive damage in addition to the characteristic episodes
of inflammatory activity, with a growing body of evidence
showing that this condition needs to be viewed not simply as
series of intermittent flares but as a disease with a
continuous pathology9 (Fig. 1). There are also emerging
data to suggest that mucosal healing in CD and UC patients is
associated with a reduction in the need for subsequent
surgical resection over the following decade.10 The role of
Figure 1 Progression of digestive damage and inflammatory
activity in a theoretical patient with CD. This graphical
representation shows that each symptom flare produces
cumulative damage to the digestive tract. The role of early
treatment in delaying or preventing structural bowel damage
and associated disability is an important area of current
research. Figure reproduced and adapted from Pariente et
al,42 with permission from Lippincott Williams & Wilkins, Inc. ©
2011.
Table 1 Suggested composition of an inflammatory bowel
disease multidisciplinary team.
Core team Gastroenterologists
IBD nurse specialists
Surgeons
Radiologists
Pathologists
Specialist pharmacists
Complementary team Dieticians
Psychologists
Social workers
Paediatricians
Rheumatologists
Dermatologists
Ophthalmologists
Infectious disease specialists
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and disability is therefore an important area of research.
There is some evidence that patients treated with tumour
necrosis factor (TNF) antagonists within the first two years
after CD diagnosis will achieve better remission rates than
those in whom treatment is started between two and five
years or more than five years after diagnosis.11 Criteria that
should prompt early and intensive therapy include extensive
CD, severe upper tract disease, severe rectal disease,
complicated disease behaviour at diagnosis, complex
perianal disease, severe endoscopic lesions and failure to
thrive (in paediatric patients). There is hope that the
increasing study and use of prognostic and predictive
biomarkers may hold a key to improving and tightening
patient monitoring, management and disease control. For
example, C-reactive protein (CRP) levels appear to be
predictive of level of response to biologic therapy.12 There
are a number of on-going clinical trials, including the CALM
(NCT01235689) and REACT-2 (NCT01698307) studies, that
hope to determine the value of early and tight disease
control on clinical outcomes in CD. For patients on
treatment, there is also a need for consistent and agreed
approaches to managing loss of response, founded on disease
and drug monitoring protocols and algorithms that ensure
appropriate treatment intensification or treatment
switching, according to patient needs.13–162. What do we do well and what difference has
it made?
The best care for patients with IBD appears to come from
services provided by a multidisciplinary team (MDT)
(Table 1), ideally delivered at an IBD centre of excellence
and founded on current consensus.17–19 High-volume IBD
centres have been shown to provide better surgical
outcomes than non-specialist centres.20 Care delivered by
a MDT at an IBD centre of excellence offers an effective
model for long-term care of patients with IBD and reflectsthe need to be adaptable and responsive to patients with
changeable and progressive disease.
At St Mark's Hospital in London, the IBD team comprises
15 gastroenterologists, 10 surgeons and five specialist
nursing teams (including an IBD nursing team, stoma and
pouch nurses, nutrition nurses and an endoscopy nursing
team), as well as pharmacy, radiology, paediatrics and
clinical research. Weekly IBD MDT meetings take place,
including a main IBD MDT meeting, a virtual biologics
meeting, a dysplasia/polyp meeting, a psychosocial meeting
and an IBD executive meeting (for the purposes of service
planning). The IBD MDT meeting allows for MDT consider-
ation of complex patients and/or diagnostic dilemmas to
create a clear care plan. The virtual biologics meeting is
designed to ensure a consistent approach to treatment and
monitoring for patients receiving anti-TNF therapy. The
patient's general practitioner and the relevant funding body
are also provided with an update on the patient's progress to
ensure that treatment continues without interruption.
Meetings are documented to allow appropriate correspon-
dence regarding clinical decisions to general practitioners
and patients. Patients with chronic diseases such as IBD need
to learn self-management while having a supportive network
and access to prompt care and advice when unwell. The IBD
specialist nurse plays a key liaison role with the patient,
acting as their advocate at MDT meetings and ensuring that
the focus is on managing IBD in the context of the patient's
life, rather than just in terms of disease activity. Specialist
nurses are a key point of access for patients for education
and information and are also a means for patients to share
and discuss the impact of disease on everyday life, specific
symptom difficulties and the complexities of living with a
somewhat “invisible” disease.21 What IBD patients want
from nurses is to be listened to, and to be given information,
honest dialogue about their disease, a relationship or
connection and hope of a more normal life. A continuing
focus of nurses is to determine a patient's ability to manage
their illness in the context of their life, by listening to and
supporting patients and providing care and information
according to individual patient needs. Providing a dedicated
IBD telephone line for patients is an example of a tool that
allows swift appropriate access to advice and care,
922 J. Panés et al.particularly during periods of ill-health.22 Virtual clinics and
networking may also provide models through which to
deliver high-quality, expert integrated patient care in IBD.23
IBD centres of excellence may not be the norm for IBD
care in every jurisdiction. For example, very few countries
allocate specialist nursing staff as permanent personnel in
IBD units. Nevertheless, this kind of model can provide us
with opportunity to evaluate best-practice strategies and
tailor these to other contexts as resources allow.
3. Fostering physician–patient collaboration
Fostering collaboration between the patient and their
healthcare team is particularly important in terms of
optimising treatment adherence. Patients need to accept
the need for a therapeutic intervention, then adhere and
persist with that intervention, in order to succeed in
reaching the goals of remission, prevention of damage and
prevention of physical disability. The motivation to start and
continue on a medication is known to be influenced by how
patients judge their personal need for medication relative to
their concerns about potential adverse events.24 A
cross-sectional survey of 1871 members of the National
Association for Colitis and CD in the UK highlighted that
acceptance of the need for a treatment is the primary
challenge to adhering to maintenance treatment.25 The
literature provides a number of reports showing that
patients with IBD struggle to adhere to their prescribed
medication over time. For example, while more than 90% of
CD patients reported good adherence to thiopurine therapy
at 3 months,26 another study found that only 26% of patients
reported adhering to their prescribed therapy after
4 years.27 A systematic review of 13 observational studies
of adherence to anti-TNF therapy in IBD found a pooled
treatment adherence rate of 83% (37–96%) with lower
adherence rates in UC than in CD.28 Often poor adherence
is unintentional (such as forgetting to take medication or
taking medication incorrectly) and is therefore preventable.
Sometimes, however, adherence is intentional with strong
predictors of intentional non-adherence which include
concerns about treatment side effects, beliefs about illness,
the perceived need for treatment and perceptions regarding
treatment efficacy (Table 2).29 Even intentional
non-adherence can be reduced by addressing patient
misconceptions or beliefs about the disease and itsTable 2 Top reasons for medication non-fulfilment and
non-persistence in patients with chronic disease in the USA.29
Survey participants were selected from the Harris Interactive
Chronic Illness Panel. Of the 19,794 respondents eligible for
the non-persistence analysis, 2756 reported non-persistence
for at least one prescription in the previous year and were
included in the analysis.
Financial hardship
Fear or experience of side effects
Generic concerns about medications
Lack of perceived need for medication
Change in health insurance or drug benefits
Did not believe that condition was life-threateningtreatments. In the UK, the National Institute for Health
and Clinical Excellence guidelines on medicine adherence
stress that patient involvement is key to improving adher-
ence (Fig. 2).30 Furthermore, a meta-analysis has shown that
healthcare professional (HCP) communication significantly
and positively correlates with improved patient adher-
ence.31 Physician training in communication skills increased
adherence significantly and pre-treatment elicitation of
concerns predicted subsequent adherence. Programmes
that include motivational interviewing (described by Miller
and Rollnick32 as “…a collaborative, conversation style for
strengthening a person's own motivation and commitment to
change” [p. 12]) could help encourage improved under-
standing of disease and treatment, better appreciation of
risks versus benefits and ultimately improved adherence to
therapy and monitoring. Cost of treatment in relation to
income may also be a factor impacting adherence to
treatment,29 although little investigation has been per-
formed around this determinant in the IBD context.
Addressing this barrier to treatment requires the participa-
tion of health system engineers, payers, patient groups and,
of course, the IBD treatment industry.
More research is needed into why patients with
immune-mediated inflammatory diseases (IMIDs) have treat-
ment adherence difficulties. The ALIGN study (UKRN ID:
12782) is a multinational cross-sectional study to determine
patient-specific and general beliefs in patients with IMIDs;
7300 patients with one of six diagnoses will be assessed in 35
countries. ALIGN will use a validated questionnaire to collect
data on beliefs and concerns that will be correlated with
disease and treatment history.4. Communicating benefit/risk to patients
Patients who understand the benefits and risks of a disease
management plan are likely to be more accepting of it and
willing to share in and follow their treatment and monitoring
schedules. In addition, a study in patients with CD has shown
that patients are willing to trade risks incurred by therapies
for benefits associated with their use.33 Patients completed
choice-format conjoint trade-off tasks involving hypotheti-
cal treatments with varying efficacy and risk levels. Benefits
and risks were described in terms of daily symptoms and
activity limitations, serious complications of CD, time
between flare-ups, exposure to steroids and risk of serious
adverse events known to be associated with CD treatment
(for example, progressive multifocal leukoencephalopathy,
serious infections and lymphoma). Patients were willing to
accept elevated risks in exchange for clinical efficacy,
interestingly at an order of magnitude greater than those
known to be associated with IBD drug therapy. However,
communicating risks and benefits to patients is not neces-
sarily easy as one cannot assume that the patient has an
ability to understand even simple statistical terms. In
addition, the way that risks and benefits are presented can
be misinterpreted by the patient. For example, in a study at
a US tertiary care centre, patients asked to choose between
two equally efficacious drugs – drug R (said to decrease
relative risk of death by 80%) and drug A (said to prevent
eight deaths in 100 people) – were more likely to choose
drug R.34 In addition, “denominator neglect” can lead to
Figure 2 Summary of the UK National Institute for Health and Clinical Excellence care pathway for supporting treatment adherence
in patients with chronic diseases.30 The recommendations highlight the importance of patient involvement in making decisions about
medicines as a key to increasing acceptance.
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is important to present patients with data in a consistent
statistical format to allow them to make valid comparisons.
This means using absolute rather than relative risk, using the
same denominator across different scenarios, explaining
percentages as fractions and avoiding inaccurate terms.36
Icon arrays can be very helpful in illustrating benefit and risk
data (Fig. 3) and graphical depiction may be helpful
depending on a patient's graph literacy skills.35–37 The
future of communicating risks and benefits may lie in system
dynamics modelling where data are collected on the disease
course and its alteration by different treatments, and then
personalised to the patient based on a number of demo-
graphic and phenotypic inputs and presented in an easily
understood graphical format.36Figure 3 An example of a simple icon array to illustrate and explain
10,000 patients can be used to indicate percentages b1%.5. Working within the healthcare system to
improve carePayers have a vested interest in ensuring that patients with
IBD receive optimal early care with a goal of reducing
long-term disease progression and disability. Nevertheless,
earlier care may have a more immediate cost associated
with it. State healthcare providers face the challenge of
achieving the best health outcomes from available funding
across whole populations and may, therefore, be more
concerned with treatment than prevention. Healthcare
funds in the European Union typically operate within the
Association Internationale de la Mutualité (AIM: a 46 member
mutual comprising 25 countries and reflecting 85% oftreatment benefit and risk data to patients. Arrays with 1000 or
924 J. Panés et al.members of the EU) or the European Social Insurance
Platform (ESIP). These mutuals in health insurance work
together in their approach to chronic clinical conditions by
seeking the most effective means of reimbursement of care
costs. Furthermore, they are supportive of new models of
care that recognise that the societal costs of chronic
diseases are impacted by measures that target prevention,
individualise care, reduce hospitalisations and limit disabil-
ity. AIM strives towards integrated customised care — that is,
efficient care that integrates primary and secondary care
services, considers service packages and medical and social
care, and is customised to focus on lifetime periods and risk
management as well as on individual case management
needs. Integrated services are supportive of early disease
diagnosis and the re-use of data to help predictive modelling
and enrolment of patients into care schemes. Health payers
are also supportive of coaching programmes and tools that
improve patient self-management and empowerment (such
as electronic personal health records). Such measures may
be used in pay-for-performance programmes. Improvement
in the care of patients with chronic disease is possible by
creating both political and healthcare service structures
that are willing, ready and able to deliver new services
offering earlier diagnosis and treatment. Payers are impor-
tant stakeholders and only by integrating patient and payer
perspectives can the burden of chronic diseases be effi-
ciently and effectively tackled.6. The future — what needs to be doneIn the future, developments in disease phenotyping and
genotyping may help inform earlier intervention. A plethora
of new and emerging therapeutic agents and interventions
affected through differing mechanisms of action should also
help improve future management of IBD.38 Improving
patient–physician communication and supporting patients
in their understanding of the evidence base are also
important for ensuring patient commitment and involve-
ment in the long-term management of their condition.39–41
There is also a desire to create more IBD centres of
excellence and to develop IBD networks to ensure a
consistent level of care across different settings — working
alone is no longer acceptable. Finally, improved communi-
cation may hold the key to empowering and allowing
patients to actively participate in disease management.
However, as with pharmacological interventions, quality
interventions also need evaluated on evidence. While
structure and process measures, such as those described in
this paper, improve the care that we give to our patients
with IBD, the tangible impact of these strategies on disease
outcomes has yet to be clearly established. Robust reporting
systems need to be implemented so that we can evaluate
whether changes in structure and process definitively drive
better meaningful clinical outcomes. Furthermore, the
cost-effectiveness of such measures needs to be carefully
considered, particularly in the current economic climate,
which is characterised by the disintegration of social security
systems due to austerity measures. It is likely that quality of
care and accessibility to treatment will continue to be a
primary focus for professional and patient associationsacross the world as we strive to improve outcomes for our
patients with IBD.
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